A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
To identify strategies for reducing emesis induced by the CHOP regimen, which includes high-dose steroids, we prospectively evaluated the efficacy of palonosetron in Japanese patients. Palonosetron was administered at a dose of 0.75 mg via intravenous injection over 30 min before chemotherapy on day 1. Patients kept diaries of chemotherapy-induced nausea and vomiting (CINV) incidence from the start of chemotherapy until 168 h afterwards, in which they documented the occurrence and severity of nausea, vomiting, anorexia, and the use of rescue medication. The primary endpoint was the overall occurrence rate of nausea, vomiting, and anorexia; these rates were 56, 12, and 62 %, respectively, including all grades. The rates and severity of symptoms tended to worsen 120-168 h after completing oral prednisolone. We defined complete response (CR) as no vomiting and no use of rescue therapy. The CR rates of post palonosetron 0.75 mg treatment in the acute (0-24 h), delayed (24-168 h), and overall phases (0-168 h) were 86, 66, and 62 %, respectively. Antiemetic strategies of CHOP regimen for day 6 and, thereafter, should be investigated.
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. yhmiyata@med.kobe-u.ac.jp.|Division of Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan. yhmiyata@med.kobe-u.ac.jp.
Yoshiharu
Y
Miyata
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Kimikazu
K
Yakushijin
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Yumiko
Y
Inui
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Yoshinori
Y
Imamura
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Hideaki
H
Goto
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Yu
Y
Mizutani
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Keiji
K
Kurata
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Seiji
S
Kakiuchi
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.|Division of Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
Yukinari
Y
Sanada
Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe, Japan.
Yosuke
Y
Minami
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Shinichiro
S
Kawamoto
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Katsuya
K
Yamamoto
Division of Hematological Malignancy, Kita-Harima Medical Center, Ono, Japan.
Mitsuhiro
M
Ito
Division of Hematology, Hyogo Cancer Center, Akashi, Japan.
Ryo
R
Tominaga
Division of Hematology, Hyogo Cancer Center, Akashi, Japan.
Hiroshi
H
Gomyo
Division of Hematology, Hyogo Cancer Center, Akashi, Japan.
Ishikazu
I
Mizuno
Division of Hematology, Hyogo Prefectural Awaji Medical Center, Sumoto, Japan.
Tetsuhiko
T
Nomura
Division of Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
Koichi
K
Kitagawa
Division of Hematological Malignancy, Kita-Harima Medical Center, Ono, Japan.
Takeshi
T
Sugimoto
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.|Division of Hematology, Hyogo Cancer Center, Akashi, Japan.
Tohru
T
Murayama
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Hiroshi
H
Matsuoka
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Hironobu
H
Minami
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D007564:Japan / Q000453:epidemiology; D008223:Lymphoma / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D000077924:Palonosetron; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D011812:Quinuclidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*; D055815:Young Adult
D000932:Antiemetics; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone
5-HT3 receptor antagonist; CHOP; Chemotherapy-induced nausea and vomiting; Malignant lymphoma; Palonosetron